Literature DB >> 30661631

EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set.

Simone Kreimeier1, Wolfgang Greiner2.   

Abstract

OBJECTIVES: Interest in the measurement of health-related quality of life (HRQoL) in children and adolescents has been increasing, and appropriate instruments are required for this target group. This article focuses on the EQ-5D-Y instrument, presenting an overview of its characteristics, development, and current use, and includes a discussion of methodological and conceptual issues related to the valuation of child health and the development of an EQ-5D-Y value set.
METHODS: This article brings together the experiences of the research team that developed and validated the EQ-5D-Y, supplemented by information derived from EQ-5D-Y study registrations on the EuroQol Group's website.
RESULTS: EQ-5D-Y is a child-specific and age-appropriate measure of HRQoL. Study registration data show that the instrument's use has steadily increased since its first publication. It has been used in various types of studies and in different disease areas. Currently there is no value set for EQ-5D-Y, and so its use in cost-utility analysis (CUA) is limited. There are methodological and conceptual issues that affect the design of valuation studies for child health. Issues that are discussed include the need for separate value sets for children and adolescents, the choice of appropriate reference samples and valuation techniques, and the framing of the tasks.
CONCLUSIONS: Research on EQ-5D-Y and its use has increased in the last years. Further research is required to clarify methodological issues regarding health state valuation in children and adolescents. This will support the development of a value set for EQ-5D-Y and the use of EQ-5D-Y in CUA.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EQ-5D-Y; adolescents; children; health-related quality of life (HRQoL); valuation of health states

Mesh:

Year:  2019        PMID: 30661631     DOI: 10.1016/j.jval.2018.11.001

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  31 in total

1.  Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis.

Authors:  Jiaer Lin; Carlos King Ho Wong; Jason Pui Yin Cheung; Prudence Wing Hang Cheung; Nan Luo
Journal:  Eur J Health Econ       Date:  2022-02-04

2.  Health-Related Quality of Life in Thai Children with Thalassemia as Evaluated by PedsQL and EQ-5D-Y: A Single-Center Experience.

Authors:  Phakatip Sinlapamongkolkul; Pacharapan Surapolchai
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-07-01       Impact factor: 2.576

3.  Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst Scaling.

Authors:  Kim Dalziel; Max Catchpool; Borja García-Lorenzo; Inigo Gorostiza; Richard Norman; Oliver Rivero-Arias
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

4.  Impact of sleep duration, physical activity, and screen time on health-related quality of life in children and adolescents.

Authors:  Carlos K H Wong; Rosa S Wong; Jason P Y Cheung; Keith T S Tung; Jason C S Yam; Michael Rich; King-Wa Fu; Prudence W H Cheung; Nan Luo; Chi Ho Au; Ada Zhang; Wilfred H S Wong; Jiang Fan; Cindy L K Lam; Patrick Ip
Journal:  Health Qual Life Outcomes       Date:  2021-05-12       Impact factor: 3.186

5.  Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.

Authors:  Takeru Shiroiwa; Shunya Ikeda; Shinichi Noto; Takashi Fukuda; Elly Stolk
Journal:  Med Decis Making       Date:  2021-03-23       Impact factor: 2.583

6.  'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.

Authors:  Mimmi Åström; Helen Conte; Jenny Berg; Kristina Burström
Journal:  Qual Life Res       Date:  2022-02-24       Impact factor: 3.440

7.  Effect of RaceRunning on cardiometabolic disease risk factors and functional mobility in young people with moderate-to-severe cerebral palsy: protocol for a feasibility study.

Authors:  Jennifer Ryan; Nicola Theis; Pelagia Koufaki; Shaun Phillips; Nana Anokye; Georgia Andreopoulou; Fiona Kennedy; Kavi C Jagadamma; Petra vanSchie; Hannah Dines; Marietta L van der Linden
Journal:  BMJ Open       Date:  2020-07-01       Impact factor: 2.692

8.  Psychometric properties of the Japanese version of the EQ-5D-Y by self-report and proxy-report: reliability and construct validity.

Authors:  T Shiroiwa; T Fukuda; K Shimozuma
Journal:  Qual Life Res       Date:  2019-06-26       Impact factor: 4.147

9.  Effectiveness and cost-effectiveness of guided Internet- and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHCD): study protocol for a multicentre randomized controlled trial.

Authors:  Frederike Lunkenheimer; Matthias Domhardt; Agnes Geirhos; Reinhold Kilian; Annabel S Mueller-Stierlin; Reinhard W Holl; Thomas Meissner; Kirsten Minden; Morten Moshagen; Ramona Ranz; Cedric Sachser; Doris Staab; Petra Warschburger; Harald Baumeister
Journal:  Trials       Date:  2020-03-12       Impact factor: 2.279

10.  Measurement Properties of the Online EuroQol-5D-Youth Instrument in Children and Adolescents With Type 1 Diabetes Mellitus: Questionnaire Study.

Authors:  Karina Mayoral; Luis Rajmil; Marta Murillo; Olatz Garin; Angels Pont; Jordi Alonso; Joan Bel; Jacobo Perez; Raquel Corripio; Gemma Carreras; Javier Herrero; Jose-Maria Mengibar; Dolors Rodriguez-Arjona; Ulrike Ravens-Sieberer; Hein Raat; Vicky Serra-Sutton; Montse Ferrer
Journal:  J Med Internet Res       Date:  2019-11-12       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.